Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial - Craddock, C; Houlton, A; Ferguson, P; Raghavan, M; Fox, S; Dudley, L; Quek, L; Cavenagh, J; Dennis, M; McMullin, M; Pillai, S; Kelly, R; et al. (American Society of Hematology, 2016)